These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 15532422)

  • 1. [Cardiovascular prevention: new study, new guidelines. The effort keeping the heart healthy].
    Einecke D
    MMW Fortschr Med; 2004 Sep; 146(38):4-6, 8. PubMed ID: 15532422
    [No Abstract]   [Full Text] [Related]  

  • 2. [HeartScore: new "national" computer program for prevention. The German risk was overestimated until now].
    Aumiller J
    MMW Fortschr Med; 2006 May; 148(19):8. PubMed ID: 16736695
    [No Abstract]   [Full Text] [Related]  

  • 3. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS).
    Li JJ; Lu ZL; Kou WR; Chen Z; Wu YF; Yu XH; Zhao YC;
    J Clin Pharmacol; 2009 Aug; 49(8):947-56. PubMed ID: 19602720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of methods to identify individuals at increased risk of cardiovascular disease in Italian cohorts.
    Giavarina D; Barzon E; Cigolini M; Mezzena G; Soffiati G
    Nutr Metab Cardiovasc Dis; 2007 May; 17(4):311-8. PubMed ID: 17434054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Distribution of cardiovascular risk factors in coronary patients in Sahel, Tunisia].
    Lihioui M; Boughzala E; Ben Farhat M; Ammar H; Chaouech A; Jemaa R; Kaabachi N
    East Mediterr Health J; 2007; 13(3):536-43. PubMed ID: 17687825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular disease prevention tailored for women.
    Engberding N; Wenger NK
    Expert Rev Cardiovasc Ther; 2008 Sep; 6(8):1123-34. PubMed ID: 18793115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Outcome of elderly patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction" CCI-06-1046.R1.
    Dean LS
    Catheter Cardiovasc Interv; 2007 Oct; 70(4):491. PubMed ID: 17896410
    [No Abstract]   [Full Text] [Related]  

  • 9. What is my risk of developing cardiovascular disease?
    Graham IM; Cooney MT; Dudina A; Squarta S
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S2-7. PubMed ID: 19675432
    [No Abstract]   [Full Text] [Related]  

  • 10. Accelerated atherosclerosis in prolonged maintenance hemodialysis.
    Lindner A; Charra B; Sherrard DJ; Scribner BH
    N Engl J Med; 1974 Mar; 290(13):697-701. PubMed ID: 4813742
    [No Abstract]   [Full Text] [Related]  

  • 11. The burden of hyperlipidaemia and diabetes in cardiovascular diseases.
    Merkler M; Reiner Z
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():1-3. PubMed ID: 18001311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial.
    Dagenais GR; Yi Q; Lonn E; Sleight P; Ostergren J; Yusuf S;
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):75-81. PubMed ID: 15703510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary prevention of cardiovascular diseases by lipid-lowering treatment in German general practice: results from GPs ignoring guidelines and risk calculators.
    Oriol-Zerbe C; Abholz HH
    Eur J Gen Pract; 2007; 13(1):27-34. PubMed ID: 17366291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardiovascular prediction rules: problems for application in practice results of a workshop].
    Eichler K; Biller-Andorno N; Traindl O; Tschudi P; Bachmann LM; Steurer J
    Praxis (Bern 1994); 2006 Nov; 95(45):1751-6. PubMed ID: 17205931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
    Knopp RH; d'Emden M; Smilde JG; Pocock SJ
    Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [HeartScore, PC-based cardiovascular risk assessment. A cooperation between general practitioners and cardiologists].
    Perk J; Thomsen T
    Lakartidningen; 2005 Jun 13-26; 102(24-25):1893-5. PubMed ID: 16044769
    [No Abstract]   [Full Text] [Related]  

  • 17. [When will fibrinogen screening become available?].
    Ernst E
    Dtsch Med Wochenschr; 1991 Dec; 116(49):1888-9. PubMed ID: 1743100
    [No Abstract]   [Full Text] [Related]  

  • 18. Predicting the coronary risk in primary and secondary prevention. What is the difference?
    Simon J; Rosolova H
    Eur Heart J; 2001 Nov; 22(22):2047-9. PubMed ID: 11686660
    [No Abstract]   [Full Text] [Related]  

  • 19. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. beta-Blockade in noncardiac surgery: outcome at all levels of cardiac risk.
    Kaafarani HM; Atluri PV; Thornby J; Itani KM
    Arch Surg; 2008 Oct; 143(10):940-4; discussion 944. PubMed ID: 18936371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.